Purdue Pharma will sell the facility to Novo Nordisk for an undisclosed amount. It will continue operations at its manufacturing plant in Wilson, N.C.
The embattled drugmaker, which is facing more than 1,000 lawsuits linked to the U.S. opioid crisis, declined to comment on whether the closure and sale will result in layoffs.
“Given the market dynamics and expected demand for our current portfolio of marketed products, the continued operation of [the Durham plant] can no longer be justified,” Purdue CEO and President Craig Landau said in a letter to employees, cited by the Advocate. “Further, a thorough analysis of Purdue’s current and future business requirements shows that with additional staffing and the continued leadership of personnel already in place, our Wilson facility is in a position to meet today’s product requirements as well as enable the growth strategy for Purdue and all of its subsidiaries going forward.”
More articles on pharmacy:
Pfizer to merge off-patent business with Mylan
Senate panel advances drug-pricing legislation
Average chief pharmacy officer salary by state
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
